131I-Apamistamab
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for 131I-Apamistamab, covering 2025-06-11 to 2025-09-10. Get the full timeline:
Most recent: Clinical Trial Update: Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML [Phase 2, Phase 3]